Cite
HARVARD Citation
Morschhauser, F. et al. (n.d.). INTERIM REPORT FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMAS. Hematological oncology. pp. 24-25. [Online].